What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
FiercePharma2d
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
American Association of Individual Investors3d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
BioPharma Dive11d
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
Cystic Fibrosis Therapeutics Market Booming Worldwide With Analysis, Growth, Upcoming Trend & Future Scope By 2033
The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...